Latest news

Debiopharm releases results of 3 key oncology compound programs at the 2019 American Association for Cancer Research (AACR) Conference in…

Debiopharm International SA Announces Dosing of First Patient in a Combination Trial of Debio 1143 and Avelumab in Patients with…

Debiopharm International SA Announces Completion of Enrollment in Phase I/II Clinical Trial with Debio 1143 in SCCHN

Debiopharm International SA Announces Clinical Collaboration with the Merck-Pfizer Alliance in Cancer Immunotherapy

Debiopharm International SA initiates clinical phase II study evaluating Debio 1143 in Ovarian Cancer

FDA grants Orphan Drug Designation to Debiopharm International SA’s IAP inhibitor Debio 1143 in the treatment of ovarian cancer

EMA grants Orphan Drug Designation to Debiopharm International SA’s IAP inhibitor Debio 1143 in the treatment of Ovarian Cancer

Debiopharm International SA presents positive preliminary results from Phase 1 trials in the development of the IAP inhibitor Debio 1143…

Debiopharm International SA announces results of 2 key oncology programs at 2015 AACR Conference